Citryll

About Citryll

Citryll is a biotech company focused on pioneering transformative treatments for immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a key driver of inflammation. The company aims to address unaddressed biology in diseases like Rheumatoid Arthritis and Hidradenitis Suppurativa through its innovative therapeutic approaches.

Products & Services

CIT-013:A first-in-class monoclonal antibody with a dual mode of action that inhibits NET formation and enhances NET clearance, targeting inflammation in diseases like Rheumatoid Arthritis and Hidradenitis Suppurativa.

Specialties

Immune-mediated inflammatory diseases Neutrophil Extracellular Traps (NETs) targeting Rheumatoid Arthritis treatment Hidradenitis Suppurativa treatment Monoclonal antibody development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 85000000 MR: - FA: EUR 85 Million FAN: 85000000	D: 2024-12-09 FD: 2024-12-09	9 investors

Series B Latest

2024-12-09

$85.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Eduardo Bravo

CEO

E

Eric Meldrum

CSO

M

Maarten Kraan

CMO

R

Renato Chirivi

CTO

S

Sjoerd van Gorp

COO

T

Tim Schenk

Chief Business Officer

View 36 more team members with Pro

Unlock Full Team Directory

Recent News

Citryll Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised